As Chief of the Division of Pediatric Hematology and Oncology at the Rutgers Cancer Institute of New Jersey, Dr. Peter Cole is committed to improving outcomes for children with cancer or blood disorders through a coordinated program of clinical and laboratory-based research. Dr. Cole's current research program focuses on improving curative therapy for children and young adults with hematologic malignancies.
In collaboration with the Children’s Oncology Group and the DFCI Acute Lymphoblastic Leukemia Consortium, he has led clinical trials testing novel therapeutic approaches as well as correlative studies to explain healthcare disparities in cancer treatment outcomes. Dr. Cole's laboratory research focuses on reducing the neurotoxic effects of cancer therapy, using an animal model to study pathophysiology and test protective interventions, and using patient samples to identify genetic predictors of clinical toxicity.
- Insurance and Neighborhood Opportunity Predict Adverse Events in Children with Acute Lymphoblastic Leukemia (217-1)
- Rutgers Cancer Institute of New Jersey
- New Brunswick, New Jersey